RU2014151992A - Лечение воспалительных заболеваний глаз с применением лахинимода - Google Patents
Лечение воспалительных заболеваний глаз с применением лахинимода Download PDFInfo
- Publication number
- RU2014151992A RU2014151992A RU2014151992A RU2014151992A RU2014151992A RU 2014151992 A RU2014151992 A RU 2014151992A RU 2014151992 A RU2014151992 A RU 2014151992A RU 2014151992 A RU2014151992 A RU 2014151992A RU 2014151992 A RU2014151992 A RU 2014151992A
- Authority
- RU
- Russia
- Prior art keywords
- lachinimod
- pharmaceutically acceptable
- acceptable salt
- effective amount
- therapeutically effective
- Prior art date
Links
- 208000027866 inflammatory disease Diseases 0.000 title claims abstract 4
- 150000003839 salts Chemical class 0.000 claims abstract 37
- 206010046851 Uveitis Diseases 0.000 claims abstract 14
- 208000030533 eye disease Diseases 0.000 claims abstract 13
- 230000002757 inflammatory effect Effects 0.000 claims abstract 13
- 208000024891 symptom Diseases 0.000 claims abstract 8
- 206010061218 Inflammation Diseases 0.000 claims abstract 7
- 230000004054 inflammatory process Effects 0.000 claims abstract 7
- 210000001519 tissue Anatomy 0.000 claims abstract 6
- 208000023275 Autoimmune disease Diseases 0.000 claims abstract 5
- 206010015943 Eye inflammation Diseases 0.000 claims abstract 5
- 239000003814 drug Substances 0.000 claims abstract 5
- 206010010741 Conjunctivitis Diseases 0.000 claims abstract 4
- 210000004087 cornea Anatomy 0.000 claims abstract 4
- 210000000744 eyelid Anatomy 0.000 claims abstract 4
- 210000004561 lacrimal apparatus Anatomy 0.000 claims abstract 4
- 210000001525 retina Anatomy 0.000 claims abstract 4
- 238000004519 manufacturing process Methods 0.000 claims abstract 3
- 210000005112 optic tract Anatomy 0.000 claims abstract 3
- 230000004421 optic tracts Effects 0.000 claims abstract 3
- 208000002691 Choroiditis Diseases 0.000 claims abstract 2
- 206010010755 Conjunctivitis viral Diseases 0.000 claims abstract 2
- 206010061818 Disease progression Diseases 0.000 claims abstract 2
- 206010022941 Iridocyclitis Diseases 0.000 claims abstract 2
- 208000003971 Posterior uveitis Diseases 0.000 claims abstract 2
- 208000005914 Viral Conjunctivitis Diseases 0.000 claims abstract 2
- 201000004612 anterior uveitis Diseases 0.000 claims abstract 2
- 201000007032 bacterial conjunctivitis Diseases 0.000 claims abstract 2
- 230000006378 damage Effects 0.000 claims abstract 2
- 230000005750 disease progression Effects 0.000 claims abstract 2
- 201000007407 panuveitis Diseases 0.000 claims abstract 2
- 230000002207 retinal effect Effects 0.000 claims abstract 2
- 210000003979 eosinophil Anatomy 0.000 claims 5
- 239000000243 solution Substances 0.000 claims 5
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims 4
- 208000002205 allergic conjunctivitis Diseases 0.000 claims 4
- 208000024998 atopic conjunctivitis Diseases 0.000 claims 4
- 239000007788 liquid Substances 0.000 claims 4
- 210000000795 conjunctiva Anatomy 0.000 claims 3
- 230000001939 inductive effect Effects 0.000 claims 2
- 230000008595 infiltration Effects 0.000 claims 2
- 238000001764 infiltration Methods 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000003186 pharmaceutical solution Substances 0.000 claims 2
- 206010002198 Anaphylactic reaction Diseases 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 208000003455 anaphylaxis Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 206010067671 Disease complication Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261655526P | 2012-06-05 | 2012-06-05 | |
| US61/655,526 | 2012-06-05 | ||
| PCT/US2013/044058 WO2013184650A2 (en) | 2012-06-05 | 2013-06-04 | Treatment of ocular inflammatory diseases using laquinimod |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2014151992A true RU2014151992A (ru) | 2016-07-27 |
Family
ID=49671002
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014151992A RU2014151992A (ru) | 2012-06-05 | 2013-06-04 | Лечение воспалительных заболеваний глаз с применением лахинимода |
Country Status (10)
| Country | Link |
|---|---|
| US (6) | US20130324574A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2854767A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2015523986A (cg-RX-API-DMAC7.html) |
| AR (1) | AR092842A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2874767A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL235874A0 (cg-RX-API-DMAC7.html) |
| RU (1) | RU2014151992A (cg-RX-API-DMAC7.html) |
| TW (1) | TW201400117A (cg-RX-API-DMAC7.html) |
| UY (1) | UY34843A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2013184650A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2014009373A (es) | 2012-02-03 | 2014-08-27 | Teva Pharma | Uso de laquinimod para tratar pacientes con enfermedad de crohn que fallaron en la terapia de anti-tnfa de primera linea. |
| TW201410244A (zh) | 2012-08-13 | 2014-03-16 | Teva Pharma | 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ） |
| US20150141458A1 (en) * | 2013-11-15 | 2015-05-21 | Teva Pharmaceutical Industries, Ltd. | Treatment of Glaucoma Using Laquinimod |
| WO2015168103A1 (en) | 2014-04-29 | 2015-11-05 | Teva Pharmaceutical Industries Ltd. | Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status |
| IL293469B2 (en) * | 2019-12-19 | 2024-04-01 | Active Biotech Ab | Compounds for treatment of eye diseases associated with excessive vascularisation |
| US20240180819A1 (en) * | 2021-04-01 | 2024-06-06 | Active Biotech Ab | Laquinimod formulation for ocular use |
Family Cites Families (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3024257A (en) | 1961-04-10 | 1962-03-06 | Frosst & Co Charles E | Stable preparations of alkali metal salts of estrone sulfate |
| FR2340735A1 (fr) | 1976-02-11 | 1977-09-09 | Roussel Uclaf | Nouveaux derives de l'acide 3-quinoleine carboxylique, leur procede de preparation et leur application comme medicament |
| IE52670B1 (en) | 1981-03-03 | 1988-01-20 | Leo Ab | Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation |
| DE3437232A1 (de) | 1984-10-10 | 1986-04-17 | Mack Chem Pharm | Stabilisierte injektionsloesungen von piroxicam |
| US5540934A (en) | 1994-06-22 | 1996-07-30 | Touitou; Elka | Compositions for applying active substances to or through the skin |
| US5912349A (en) | 1997-01-31 | 1999-06-15 | Pharmacia & Upjohn Company | Process for the preparation of roquinimex |
| US20030124187A1 (en) | 1997-02-14 | 2003-07-03 | Smithkline Beecham Laboratoires Pharmaceutiques, | Pharmaceutical formulations comprising amoxycillin and clavulanate |
| US6696407B1 (en) | 1997-03-21 | 2004-02-24 | The Regents Of The University Of California | Huntington's disease treatment comprising administering aldose reductase inhibitors to increase striatal CNTF |
| US6077851A (en) | 1998-04-27 | 2000-06-20 | Active Biotech Ab | Quinoline derivatives |
| SE9801474D0 (sv) * | 1998-04-27 | 1998-04-27 | Active Biotech Ab | Quinoline Derivatives |
| US6121287A (en) | 1998-07-15 | 2000-09-19 | Active Biotech Ab | Quinoline derivatives |
| SE9802549D0 (sv) | 1998-07-15 | 1998-07-15 | Active Biotech Ab | Quinoline derivatives |
| SE9802550D0 (sv) | 1998-07-15 | 1998-07-15 | Active Biotech Ab | Quinoline derivatives |
| US6133285A (en) | 1998-07-15 | 2000-10-17 | Active Biotech Ab | Quinoline derivatives |
| RS51019B (sr) | 1999-10-25 | 2010-10-31 | Active Biotech Ab. | Lekovi za lečenje malignih tumora |
| EP1365794A2 (en) | 2000-07-21 | 2003-12-03 | Lue, Tom | Prevention and treatment of sexual arousal disorders |
| US6307050B1 (en) | 2000-08-29 | 2001-10-23 | R. T. Alamo Venture I Llc | Method of synthesizing flosequinan from 4-fluoroanthranilic acid |
| US6802422B2 (en) | 2000-12-12 | 2004-10-12 | Multi-Comp, Inc. | Sealed blister assembly |
| US6706733B2 (en) | 2001-05-08 | 2004-03-16 | Dainippon Ink And Chemicals, Inc. | Quinolinone derivative formulation and its production method |
| US20030119826A1 (en) | 2001-09-24 | 2003-06-26 | Pharmacia Corporation | Neuroprotective treatment methods using selective iNOS inhibitors |
| US7560557B2 (en) | 2002-06-12 | 2009-07-14 | Active Biotech Ag | Process for the manufacture of quinoline derivatives |
| SE0201778D0 (sv) | 2002-06-12 | 2002-06-12 | Active Biotech Ab | Process for the manufacture of quinoline derivatives |
| US6875869B2 (en) | 2002-06-12 | 2005-04-05 | Active Biotech Ab | Process for the manufacture of quinoline derivatives |
| US20070292461A1 (en) | 2003-08-04 | 2007-12-20 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
| US7820145B2 (en) | 2003-08-04 | 2010-10-26 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
| US7790197B2 (en) | 2003-06-09 | 2010-09-07 | Warner-Lambert Company Llc | Pharmaceutical compositions of atorvastatin |
| US20050271717A1 (en) | 2003-06-12 | 2005-12-08 | Alfred Berchielli | Pharmaceutical compositions of atorvastatin |
| CA2528723A1 (en) | 2003-06-25 | 2005-01-06 | Elan Pharmaceuticals, Inc. | Methods and compositions for treating rheumatoid arthritis |
| US8795693B2 (en) | 2003-08-04 | 2014-08-05 | Foamix Ltd. | Compositions with modulating agents |
| US8314124B2 (en) | 2004-02-06 | 2012-11-20 | Active Biotech Ab | Crystalline salts of quinoline compounds and methods for preparing them |
| SE0400235D0 (sv) | 2004-02-06 | 2004-02-06 | Active Biotech Ab | New composition containing quinoline compounds |
| US20060004019A1 (en) | 2004-04-01 | 2006-01-05 | Ivan Lieberburg | Steroid sparing agents and methods of using same |
| EP1753445A4 (en) | 2004-05-06 | 2009-05-20 | Molichem Medicines Inc | TREATMENT OF EYE DISEASES AND EYE TREATMENTS WITH LANTIBIOTIC COMPOSITIONS |
| EP1796710A4 (en) | 2004-09-02 | 2010-05-26 | Teva Pharma | THERAPY COMBINED WITH GLATIRAMER ACETATE AND N-ACETYLCYSTEINE TO TREAT MULTIPLE SCLEROSIS |
| US7560100B2 (en) | 2004-09-09 | 2009-07-14 | Yeda Research And Development Co., Ltd. | Mixtures of polypeptides, compositions containing and processes for preparing same, for treating neurodegenerative diseases |
| US20060205822A1 (en) | 2004-12-22 | 2006-09-14 | Forest Laboratories, Inc. | 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect |
| JP5905184B2 (ja) | 2005-10-13 | 2016-04-20 | ヒューマン ジノーム サイエンシーズ， インコーポレイテッドＨｕｍａｎ Ｇｅｎｏｍｅ Ｓｃｉｅｎｃｅｓ， Ｉｎｃ． | 自己抗体陽性疾患を有する患者の処置に使用するための方法および組成物 |
| US9168286B2 (en) | 2005-10-13 | 2015-10-27 | Human Genome Sciences, Inc. | Methods and compositions for use in treatment of patients with autoantibody positive disease |
| KR101440982B1 (ko) | 2005-10-19 | 2014-09-17 | 테바 파마슈티컬 인더스트리즈 리미티드 | 라퀴니모드 나트륨의 결정 및 이의 제조방법 |
| RS52229B (sr) | 2005-10-26 | 2012-10-31 | Merck Serono Sa. | Derivati sulfonamida i njihova upotreba za modulaciju metaloproteinaza |
| US20080108641A1 (en) | 2006-02-08 | 2008-05-08 | Ajami Alfred M | Compounds for treating inflammatory disorders, demyelinating disdorders and cancers |
| US8367629B2 (en) | 2006-02-14 | 2013-02-05 | Noxxon Pharma Ag | MCP-1 binding nucleic acids and use thereof |
| WO2007100763A2 (en) | 2006-02-28 | 2007-09-07 | Elan Pharmaceuticals, Inc. | Methods of treating inflammatory and autoimmune diseases with alpha-4 inhibitory compounds |
| ES2752137T3 (es) | 2006-02-28 | 2020-04-03 | Biogen Ma Inc | Métodos para tratar enfermedades inflamatorias y autoinmunes con natalizumab |
| CA2644110A1 (en) | 2006-03-03 | 2007-09-13 | Elan Pharmaceuticals, Inc. | Methods of treating inflammatory and autoimmune diseases with natalizumab |
| US9399061B2 (en) | 2006-04-10 | 2016-07-26 | Abbvie Biotechnology Ltd | Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis |
| ATE532515T1 (de) | 2006-06-12 | 2011-11-15 | Teva Pharma | Stabile laquinimod-zubereitungen |
| WO2007146331A1 (en) | 2006-06-12 | 2007-12-21 | Teva Pharmaceutical Industries, Ltd. | Tannate salt form of polypeptide mixtures, their preparation and use |
| EP1886996A1 (en) | 2006-08-10 | 2008-02-13 | Ferrer Internacional, S.A. | 1H-Quinolin-4-one compounds, with affinity for the GABA receptor, processes, uses and compositions |
| WO2008021368A2 (en) | 2006-08-11 | 2008-02-21 | The Johns Hopkins University | Compositions and methods for neuroprotection |
| US20100136125A1 (en) | 2006-12-28 | 2010-06-03 | Jacobus Pharmaceutical Company, Inc. | Method of treating inflammatory bowel disease |
| PL2187882T3 (pl) | 2007-07-11 | 2013-05-31 | Medicinova Inc | Leczenie postępującej choroby neurodegeneracyjnej ibudilastem |
| RS53199B (sr) | 2007-12-20 | 2014-06-30 | Teva Pharmaceutical Industries Ltd. | Stabilni preparati lakvinimoda |
| WO2010001257A2 (en) | 2008-07-01 | 2010-01-07 | Actavis Group Ptc Ehf | Novel solid state forms of laquinimod and its sodium salt |
| EP2337779B1 (en) | 2008-09-03 | 2017-04-19 | Teva Pharmaceutical Industries Ltd. | 2-oxo-1,2-dihydro-quinoline modulators of immune function |
| WO2010070449A2 (en) * | 2008-12-17 | 2010-06-24 | Actavis Group Ptc Ehf | Highly pure laquinimod or a pharmaceutically acceptable salt thereof |
| EP2228367A1 (en) * | 2009-03-13 | 2010-09-15 | Almirall, S.A. | Addition salts of amines containing hydroxyl and/or carboxylic groups with amino nicotinic acid derivatives as DHODH inhibitors |
| AU2010260455A1 (en) | 2009-06-19 | 2012-02-02 | Teva Pharmaceutical Industries Ltd. | Treatment of multiple sclerosis with laquinimod |
| JP5882208B2 (ja) * | 2009-07-30 | 2016-03-09 | テバ ファーマシューティカル インダストリーズ リミティド | ラキニモドによるクローン病の治療 |
| RS55071B1 (sr) * | 2009-08-10 | 2016-12-30 | Teva Pharma | Tretman poremećaja koji su u vezi sa bdnf primenom lakvinimoda |
| CN102811610B (zh) * | 2009-12-15 | 2016-05-18 | 前瞻生物治疗公司 | 无刺激性眼科聚维酮碘组合物 |
| MX342001B (es) | 2010-03-03 | 2016-09-09 | Teva Pharmaceutical Ind Ltd * | Tratamiento de artritis por lupus usando laquinimod. |
| CN102781240A (zh) | 2010-03-03 | 2012-11-14 | 泰华制药工业有限公司 | 用拉喹莫德和甲氨蝶呤的组合治疗类风湿性关节炎 |
| BR112012021905A2 (pt) | 2010-03-03 | 2015-09-29 | Teva Pharma | tratamento de nefrite lúpica usando laquinimod |
| US20130045886A1 (en) | 2010-03-08 | 2013-02-21 | Gary Whittaker | Methods For Diagnosing Feline Coronavirus Infections |
| WO2012001647A2 (en) * | 2010-06-30 | 2012-01-05 | Compugen Ltd. | Polypeptides and uses thereof as a drug for treatment of multiple sclerosis, rheumatoid arthritis and other autoimmune disorders |
| CN102985090B (zh) | 2010-07-09 | 2014-11-26 | 泰华制药工业有限公司 | 5-氯-4-羟基-1-甲基-2-氧代-n-苯基-1,2-二氢喹啉-3-甲酰胺、其盐和用途 |
| MX2013000333A (es) | 2010-07-09 | 2013-02-26 | Teva Pharma | N-etil-n-fenil-1,2-dihidro-4-hidroxi-5-cloro-1-metil-2-oxoquinoli na-3-carboxamida deuterada, sales y usos de la misma. |
| US20140017266A1 (en) | 2010-12-03 | 2014-01-16 | The Government Of The United States, As Represented By The Secretary Of Hhs, Nih | Anti-podoplanin antibodies and methods of use |
| SG10201509831XA (en) | 2010-12-07 | 2015-12-30 | Teva Pharma | Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients |
| EP2736336A4 (en) * | 2011-07-28 | 2015-03-04 | Teva Pharma | TREATMENT OF MULTIPLE SCLEROSIS WITH A COMBINATION OF LAQUINIMOD AND INTERFERON-BETA |
| KR20140054166A (ko) | 2011-07-28 | 2014-05-08 | 테바 파마슈티컬 인더스트리즈 리미티드 | 라퀴니모드 및 글라티라머 아세테이트의 병용에 의한 다발성 경화증의 치료 |
| WO2013055907A1 (en) | 2011-10-12 | 2013-04-18 | Teva Pharmaceutical Industries Ltd. | Treatment of multiple sclerosis with combination of laquinimod and fingolimod |
| MX2014009373A (es) | 2012-02-03 | 2014-08-27 | Teva Pharma | Uso de laquinimod para tratar pacientes con enfermedad de crohn que fallaron en la terapia de anti-tnfa de primera linea. |
| CN104114172A (zh) | 2012-02-16 | 2014-10-22 | 泰华制药工业有限公司 | N-乙基-n-苯基-1,2-二氢-4,5-二-羟基-1-甲基-2-氧代-3-喹啉甲酰胺、其制备和用途 |
| US20130259856A1 (en) | 2012-03-27 | 2013-10-03 | Teva Pharmaceutical Industries, Ltd. | Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate |
| AR090885A1 (es) | 2012-05-02 | 2014-12-10 | Teva Pharma | Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple |
| TW201350467A (zh) | 2012-05-08 | 2013-12-16 | Teva Pharma | Ｎ－乙基－４－羥基－１－甲基－５－（甲基（２，３，４，５，６－五羥基己基）胺基）－２－側氧－ｎ－苯基－１，２－二氫喹啉－３－甲醯胺 |
| WO2014004733A1 (en) | 2012-06-26 | 2014-01-03 | The Regents Of The University Of California | Composition for lupus nephritis and methods of making and using the same |
| AR091706A1 (es) | 2012-07-11 | 2015-02-25 | Teva Pharma | Formulaciones de laquinimod sin agentes alcalinizantes |
| TW201410243A (zh) | 2012-08-13 | 2014-03-16 | Teva Pharma | 用於治療大麻素受體型１（ｃｂ１）媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ） |
| US20140107154A1 (en) | 2012-10-12 | 2014-04-17 | Teva Pharmaceutical Industries, Ltd. | Laquinimod for reducing thalamic damage in multiple sclerosis |
| EP2916915A4 (en) | 2012-11-07 | 2016-06-22 | Teva Pharma | LAQUINIMOD AMINE SALTS |
-
2013
- 2013-05-31 TW TW102119465A patent/TW201400117A/zh unknown
- 2013-06-03 AR ARP130101957A patent/AR092842A1/es unknown
- 2013-06-03 UY UY0001034843A patent/UY34843A/es not_active Application Discontinuation
- 2013-06-04 RU RU2014151992A patent/RU2014151992A/ru not_active Application Discontinuation
- 2013-06-04 WO PCT/US2013/044058 patent/WO2013184650A2/en not_active Ceased
- 2013-06-04 CA CA2874767A patent/CA2874767A1/en not_active Abandoned
- 2013-06-04 US US13/909,403 patent/US20130324574A1/en not_active Abandoned
- 2013-06-04 JP JP2015516113A patent/JP2015523986A/ja active Pending
- 2013-06-04 EP EP13800213.4A patent/EP2854767A4/en not_active Withdrawn
-
2014
- 2014-11-24 IL IL235874A patent/IL235874A0/en unknown
-
2017
- 2017-04-28 US US15/582,162 patent/US20170231971A1/en not_active Abandoned
- 2017-08-07 US US15/670,684 patent/US20170333420A1/en not_active Abandoned
- 2017-08-21 JP JP2017158674A patent/JP2018024677A/ja not_active Withdrawn
- 2017-11-17 US US15/816,402 patent/US11654140B2/en active Active
-
2021
- 2021-08-27 US US17/459,971 patent/US20210386731A1/en not_active Abandoned
-
2024
- 2024-07-16 US US18/774,728 patent/US20250134881A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| UY34843A (es) | 2013-12-31 |
| US20170231971A1 (en) | 2017-08-17 |
| WO2013184650A2 (en) | 2013-12-12 |
| US20130324574A1 (en) | 2013-12-05 |
| AR092842A1 (es) | 2015-05-06 |
| WO2013184650A3 (en) | 2015-07-02 |
| US20250134881A1 (en) | 2025-05-01 |
| JP2015523986A (ja) | 2015-08-20 |
| IL235874A0 (en) | 2015-01-29 |
| TW201400117A (zh) | 2014-01-01 |
| CA2874767A1 (en) | 2013-12-12 |
| US20180071275A1 (en) | 2018-03-15 |
| US11654140B2 (en) | 2023-05-23 |
| EP2854767A2 (en) | 2015-04-08 |
| EP2854767A4 (en) | 2016-04-27 |
| US20170333420A1 (en) | 2017-11-23 |
| JP2018024677A (ja) | 2018-02-15 |
| US20210386731A1 (en) | 2021-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bertens et al. | Topical drug delivery devices: A review | |
| JP2015509500A5 (cg-RX-API-DMAC7.html) | ||
| KR20160147023A (ko) | 안 질환 및 장애 치료용 화합물 | |
| RU2014151992A (ru) | Лечение воспалительных заболеваний глаз с применением лахинимода | |
| EP1938839A1 (en) | Ophthalmic compositions of parasympathetic stimulants and anti-inflammatories for use in the treatment of presbyopia | |
| CN114796205B (zh) | 用于治疗近视的方法和药物组合物 | |
| JP2023179418A (ja) | 近視の進行を制御し且つ／又は減少させるための医薬組成物 | |
| Perraut et al. | Successful treatment of Candida albicans endophthalmitis with intravitreal amphotericin B | |
| AU2021346006A1 (en) | Application of regulation of eye sclera lipid metabolism to inhibit myopia | |
| JP2015523986A5 (cg-RX-API-DMAC7.html) | ||
| Li et al. | A pilot clinical study of intravitreal injection of artesunate for ocular neovascularization | |
| JP2013515735A (ja) | 眼内でのコルチコステロイド使用に伴う眼圧の発生を減少させる方法 | |
| US20170007637A1 (en) | Pharmacological ophthalmic composition for use in the correction of presbyopia and its administration | |
| Gay et al. | Topical sympatholytic therapy for pathologic lid retraction | |
| Aydın et al. | Corneal oedema and acute anterior uveitis after two doses of travoprost | |
| KR20240050324A (ko) | 빈포세틴을 사용한 근시치료방법 | |
| RU2407491C1 (ru) | Способ лечения внутриглазных инфекций | |
| KR20230098630A (ko) | 노안의 예방, 제어 및 근절에 효과적인 저농도 투여량의 상승적 안과 조성물 | |
| RU2008107696A (ru) | Неинвазивная система доставки лекарственного средства к ткани заднего сегмента глаза с применением твердой композиции | |
| RU2836815C1 (ru) | Офтальмологические композиции для местного применения на ксантановой основе с сокращенным режимом дозирования | |
| CN116270442B (zh) | 一种用于矫正近距离视力的眼用制剂 | |
| Panwar et al. | An Ayurvedic management of diabetic retinopathy-A case report | |
| Arakelyan et al. | Role of densitometry and combination therapy in ultrasound-free femtosecond laser lens surgery in patients with refractive disorders | |
| RU2421191C1 (ru) | Способ лечения дистрофических заболеваний роговицы | |
| WO2024183783A1 (zh) | 治疗近视的药物和方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20180510 |